A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Clinical trial NCT04209465 · TERMINATED
Trial details
- NCT number
- NCT04209465
- Sponsor
- Black Diamond Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2022-09-02
- Enrollment
- 91
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.